GLP-1 Receptor Agonists May Elevate Levels of Tumor Marker CA 19-9: A Cautionary Case Study
China: Recent observations have highlighted a rare and noteworthy side effect associated with the use of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP1-RAs), commonly prescribed for the management of type 2 diabetes mellitus (T2DM). While these medications have become increasingly popular for their efficacy in controlling blood sugar levels, a specific case has drawn attention due to its unusual outcome: a significant elevation in carbohydrate antigen 19–9 (CA 19-9) without any underlying tumor presence.
The case highlights the importance of recognizing that GLP1-RAs, while beneficial for glycemic control in T2DM, can produce unexpected adverse reactions, including elevated tumor markers.
"GLP1-RAs can cause increased levels of tumor markers during the treatment of type 2 diabetes, highlighting the need for careful monitoring throughout therapy. It’s important to tailor antidiabetic management to each individual’s circumstances as necessary," the researchers wrote in Diabetes & Metabolism.
GLP-1 receptor agonists are widely prescribed for managing T2DM. While various adverse reactions have been documented, the case by Hongmei Jiao, Department of Geriatrics, Peking University First Hospital, Beijing, China, and colleagues highlights a rare occurrence where a GLP1-RA resulted in significantly elevated levels of CA 19-9 without any indication of a tumor.
This case centers on a 69-year-old Han Chinese woman with a 30-year history of type 2 diabetes mellitus, referred to the clinic for significantly elevated CA 19-9 levels at 839.8 U/ml (normal upper limit: 37.0), despite the absence of symptoms. Seventeen months prior, she started treatment with dulaglutide (1.5 mg weekly) to enhance glycemic control, alongside metformin (500 mg thrice daily) and acarbose (100 mg thrice daily). This regimen improved her blood sugar levels, reduced her appetite, and stabilized her weight after a 3 kg loss.
Her clinical examination was unremarkable, with a body mass index of 21.1 kg/m² and an HbA1c level of 6.5%. Imaging revealed a cystic lesion in the pancreatic tail and a solid mass in the right adnexal region, diagnosed as a broad ligament leiomyoma. Further tests, including PET-CT, showed no significant lesions.
Due to concerns regarding the potential impact of GLP-1 receptor agonists on pancreatic health, dulaglutide was discontinued. One week later, CA 19-9 levels began to decline, reaching normal levels (33.29 U/ml) within two months. Following the cessation of dulaglutide, her appetite improved, but her glycemic control worsened, prompting the addition of insulin to her treatment plan.
The case highlights that elevated CA 19-9 levels can occur with dulaglutide use without malignancy, underscoring the need for careful monitoring of tumor markers during treatment. Notably, levels returned to normal after discontinuation, suggesting that such increases can be drug-related. This is the first report linking dulaglutide to abnormal CA 19-9 elevation in the absence of cancer, emphasizing the importance of follow-up and further investigation when faced with rising tumor markers.
"This case report highlights a rare phenomenon linked to individual variations in response to GLP-1 receptor agonist treatment. In clinical practice, it is crucial to quickly recognize such occurrences, intervene as needed, and discontinue the medication when appropriate to avoid adverse outcomes," the researchers concluded.
Reference:
Liang, R., Fu, Z., Chen, L., Zhou, S., & Jiao, H. (2024). A very rare cause of markedly elevated CA 19–9: Glucagon-like peptide-1 receptor agonists. Diabetes & Metabolism, 50(6), 101578. https://doi.org/10.1016/j.diabet.2024.101578
